With the Easter holiday coming next month, we decided it was a good time to ask readers of Hagerty Media about their favorite ...

As a BCMA-targeting CAR T-cell therapy, CARVYKTI addresses a high unmet need in relapsed or refractory multiple myeloma patients. With promising clinical efficacy, durable responses, and growing ...